X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Lupin Ltd with ASTRAZENECA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN LTD vs ASTRAZENECA PHARMA - Comparison Results

LUPIN LTD    Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    LUPIN LTD ASTRAZENECA PHARMA LUPIN LTD/
ASTRAZENECA PHARMA
 
P/E (TTM) x 27.9 176.6 15.8% View Chart
P/BV x 2.9 26.8 10.9% View Chart
Dividend Yield % 0.6 0.0 -  

Financials

 LUPIN LTD   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    LUPIN LTD
Mar-18
ASTRAZENECA PHARMA
Mar-14
LUPIN LTD/
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs1,4651,285 114.0%   
Low Rs727634 114.7%   
Sales per share (Unadj.) Rs349.6189.6 184.4%  
Earnings per share (Unadj.) Rs5.6-0.2 -2,729.8%  
Cash flow per share (Unadj.) Rs29.63.8 769.4%  
Dividends per share (Unadj.) Rs5.000-  
Dividend yield (eoy) %0.50-  
Book value per share (Unadj.) Rs300.368.6 437.5%  
Shares outstanding (eoy) m452.0825.00 1,808.3%   
Bonus/Rights/Conversions ESOPS--  
Price / Sales ratio x3.15.1 61.9%   
Avg P/E ratio x197.2-4,712.7 -4.2%  
P/CF ratio (eoy) x37.1249.6 14.8%  
Price / Book Value ratio x3.614.0 26.1%  
Dividend payout %90.00-   
Avg Mkt Cap Rs m495,50223,988 2,065.7%   
No. of employees `00017.01.6 1,093.1%   
Total wages/salary Rs m28,6471,605 1,785.3%   
Avg. sales/employee Rs Th9,273.63,040.2 305.0%   
Avg. wages/employee Rs Th1,681.01,029.2 163.3%   
Avg. net profit/employee Rs Th147.4-3.3 -4,515.8%   
INCOME DATA
Net Sales Rs m158,0424,740 3,334.4%  
Other income Rs m1,50492 1,632.5%   
Total revenues Rs m159,5454,832 3,302.0%   
Gross profit Rs m31,475-130 -24,248.9%  
Depreciation Rs m10,859101 10,729.9%   
Interest Rs m2,0440-   
Profit before tax Rs m20,076-139 -14,453.9%   
Minority Interest Rs m-710-   
Prior Period Items Rs m350-   
Extraordinary Inc (Exp) Rs m-14,644139 -10,542.5%   
Tax Rs m2,8855 56,671.9%   
Profit after tax Rs m2,513-5 -49,363.5%  
Gross profit margin %19.9-2.7 -727.2%  
Effective tax rate %14.4-3.7 -392.1%   
Net profit margin %1.6-0.1 -1,480.4%  
BALANCE SHEET DATA
Current assets Rs m122,0952,726 4,478.3%   
Current liabilities Rs m50,9562,435 2,092.6%   
Net working cap to sales %45.06.1 732.2%  
Current ratio x2.41.1 214.0%  
Inventory Days Days8574 114.7%  
Debtors Days Days12041 294.2%  
Net fixed assets Rs m129,8761,035 12,544.8%   
Share capital Rs m90450 1,808.4%   
"Free" reserves Rs m134,866942 14,311.0%   
Net worth Rs m135,7711,716 7,912.0%   
Long term debt Rs m64,2450-   
Total assets Rs m263,0544,156 6,329.5%  
Interest coverage x10.8NM-  
Debt to equity ratio x0.50-  
Sales to assets ratio x0.61.1 52.7%   
Return on assets %1.7-0.1 -1,414.2%  
Return on equity %1.9-0.3 -623.9%  
Return on capital %3.70-  
Exports to sales %05.7 0.0%   
Imports to sales %06.5 0.0%   
Exports (fob) Rs mNA270 0.0%   
Imports (cif) Rs mNA306 0.0%   
Fx inflow Rs m53,141375 14,186.1%   
Fx outflow Rs m19,335470 4,112.5%   
Net fx Rs m33,807-96 -35,381.1%   
CASH FLOW
From Operations Rs m17,512-8 -216,196.3%  
From Investments Rs m-14,073-146 9,658.7%  
From Financial Activity Rs m-14,921862 -1,730.6%  
Net Cashflow Rs m-11,482709 -1,620.6%  

Share Holding

Indian Promoters % 46.6 0.0 -  
Foreign collaborators % 0.2 75.0 0.3%  
Indian inst/Mut Fund % 11.3 0.3 3,766.7%  
FIIs % 31.9 15.7 203.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.1 9.1 111.0%  
Shareholders   98,259 12,856 764.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare LUPIN LTD With:   BIOCON LTD  CADILA HEALTHCARE  SUVEN LIFE  PANACEA BIOTECH  WOCKHARDT LTD.  

Compare LUPIN LTD With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 284 Points Up; FMCG & Metal Stocks Top Gainers(Closing)

Indian share markets settled higher today taking cues from their Asian peers. At the closing bell, BSE Sensex ended up by 284 points.

Related Views on News

LUPIN LTD 2017-18 Annual Report Analysis (Annual Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

Here's an analysis of the annual report of LUPIN LTD for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of LUPIN LTD. Also includes updates on the valuation of LUPIN LTD.

LUPIN LTD Announces Quarterly Results (1QFY19); Net Profit Up 21.3% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, LUPIN LTD has posted a net profit of Rs 4 bn (up 21.3% YoY). Sales on the other hand came in at Rs 26 bn (up 3.2% YoY). Read on for a complete analysis of LUPIN LTD's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

This is a Must-Have Stock for Your Portfolio(The 5 Minute Wrapup)

Aug 8, 2018

Tanushree just released the permanent wealth blueprint report. This report includes three safe and steady stocks. I like one in particular. Here's why

Trading in These Times: 8% Gains in 3 Days!(Profit Hunter)

Aug 9, 2018

Here are 2 stocks you can buy right now! And there are plenty more opportunities to come...

Banks are Raising FD Rates and That's Good News(Vivek Kaul's Diary)

Aug 7, 2018

Lending to the retail segment remains strong, whereas lending to the service sector has picked up dramatically.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)

Aug 8, 2018

PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

LUPIN LTD SHARE PRICE


Aug 17, 2018 (Close)

TRACK LUPIN LTD

  • Track your investment in LUPIN LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

LUPIN LTD 8-QTR ANALYSIS

COMPARE LUPIN LTD WITH

MARKET STATS